Tirzepatide for Obesity in Patients at a Paraguay Hospital
Watches the safety and weight effects of tirzepatide in adults with obesity.
Plain-language title generated from the registry record
Registry title: Safety and Effectiveness of Tirzepatide in Patients With Obesity at Hospital de Clínicas, Paraguay
Key facts
- Where
- Asunción, ParaguaySee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with obesity, or overweight with weight-related health problems, who are treated at the Obesity Unit of Hospital de Clínicas in Paraguay and whose doctor prescribes tirzepatide.
- Age
- 18 years or older
- Sex
- All sexes
- Disease stage
- BMI 27 kg/m² or higher with weight-related health problems, or BMI 35 kg/m² or higher
- Earlier treatment
- Must not currently use other GLP-1 receptor agonist medicines. Must not have had bariatric surgery in the last 12 months.
Main reasons for not taking part
- Type 1 diabetes or secondary diabetes
- Allergy to tirzepatide
- Personal or family history of medullary thyroid cancer or MEN 2 syndrome
- Pancreatitis (acute in the last 12 months, or chronic)
- Pregnancy or breastfeeding
Read by machine on 13 November 2026.
Where in Paraguay
- Endocrinology Unit, UNA, PyAsunción, ParaguayContact: Ana Iris RamirezNo longer taking part
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- LABORATORIOS INDUFAR
- Trial code
- NCT07492563
- Record updated
- 25 March 2026
- Original description
This is a Phase 4 observational study evaluating the safety and effectiveness of tirzepatide (T.G.) manufactured by INDUFAR S.A. in 300 patients with obesity treated at the Obesity Unit of Hospital de Clínicas in Paraguay over 12 months. The primary objective is to assess the safety profile through monitoring adverse events. Secondary objectives include evaluating weight loss, metabolic parameters improvement, and treatment satisfaction in real-world clinical practice.Read full original descriptionShow less
Effectiveness and Safety of Tirzepatide (t.g.) in Patients Treated at the Obesity Unit of the Department of Endocrinology of the Hospital de Clínicas, Faculty of Medical Sciences, UNA: Phase 4 Study
This is a Phase 4 observational study evaluating the safety and effectiveness of tirzepatide (T.G.) manufactured by INDUFAR S.A. in 300 patients with obesity treated at the Obesity Unit of Hospital de Clínicas in Paraguay over 12 months. The primary objective is to assess the safety profile through monitoring adverse events. Secondary objectives include evaluating weight loss, metabolic parameters improvement, and treatment satisfaction in real-world clinical practice.
Inclusion: Age ≥18 years; BMI ≥27 kg/m² with weight-related comorbidities OR BMI ≥35 kg/m²; Clinical indication for tirzepatide per treating physician; Paraguayan citizenship or permanent residence; Residence in Asunción or Metropolitan Area or possibility to assist to regular visits; Ability to attend visits for 12 months; Ability to provide written informed consent.
Exclusion: Bariatric surgery in last 12 months; Type 1 diabetes or secondary diabetes; Known hypersensitivity to tirzepatide; Personal or family history of medullary thyroid carcinoma or MEN 2 syndrome; Severe gastrointestinal disease; Severe hepatic impairment (Child-Pugh B or C); Unstable cardiovascular disease; Active cancer (except non-melanoma skin cancer completely resected); Severe renal impairment (eGFR <30 mL/min/1.73m²); Acute pancreatitis in last 12 months or chronic pancreatitis; Pregnancy or breastfeeding; Current use of other GLP-1 receptor agonists; Participation in another interventional trial within 30 days.